- Trials with a EudraCT protocol (12)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
12 result(s) found for: Active ester.
Displaying page 1 of 1.
| EudraCT Number: 2006-005287-94 | Sponsor Protocol Number: Stulnig_PUFA1 | Start Date*: 2008-05-06 | |||||||||||
| Sponsor Name:Medizinische Universität Wien | |||||||||||||
| Full Title: Impact of n-3 Polyunsaturated Fatty Acids on Adipose Tissue Inflammation in Morbidly Obese Patients | |||||||||||||
| Medical condition: morbid obesity | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-005685-35 | Sponsor Protocol Number: FP187-301 | Start Date*: 2013-10-11 | |||||||||||
| Sponsor Name:Forward Pharma GmbH | |||||||||||||
| Full Title: A randomised, double blind, double dummy, active comparator and placebo controlled confirmative non-inferiority trial of FP187 compared to Fumaderm in moderate to severe plaque psoriasis | |||||||||||||
| Medical condition: Moderate to severe plaque psoriasis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-005135-10 | Sponsor Protocol Number: 2005-151 | Start Date*: 2006-01-19 |
| Sponsor Name:Jeppe Hagstrup Christensen | ||
| Full Title: Omacor; omega-3-acid ethyl ester 90 (N-3 PUFA) and risk faktors in HIV infected patients treated with HAART with special focus on lipids | ||
| Medical condition: Several investigations show that HIV infected patients have a higher risk for development of heart disease if treated with HAART. The investigation will evaluate the effect of fish oil on blood ... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DK (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-003219-23 | Sponsor Protocol Number: 2844 | Start Date*: 2019-06-28 | ||||||||||||||||
| Sponsor Name:University of Bristol | ||||||||||||||||||
| Full Title: CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson’s Disease): A phase 3 randomised double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson’s disease | ||||||||||||||||||
| Medical condition: This trial will investigate the effectiveness of Rivastigmine on prevention of falls in patients with Parkinson's disease | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2009-014290-40 | Sponsor Protocol Number: DU176b-D-U305 | Start Date*: 2010-02-10 | ||||||||||||||||
| Sponsor Name:Daiichi Sankyo Development Limited | ||||||||||||||||||
| Full Title: A phase 3, randomized, double-blind, double-dummy, parallel-group, multi-center, multi-national study for the evaluation of efficacy and safety of (LMW) heparin/edoxaban versus (LMW) heparin/warfar... | ||||||||||||||||||
| Medical condition: Reduction of the risk of symptomatic recurrent venous thromboembolic complications in patients with acute symptomatic deep vein thrombosis (DVT) and/or pulmonary embolism (PE) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (Completed) HU (Completed) DE (Completed) SE (Completed) FR (Completed) EE (Completed) BE (Completed) AT (Completed) ES (Completed) DK (Completed) CZ (Completed) IT (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2016-002006-39 | Sponsor Protocol Number: ESTER | Start Date*: 2016-11-14 | |||||||||||
| Sponsor Name:ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI" | |||||||||||||
| Full Title: Study on Efficacy and safety of an early proactive Switch To ElvitegraviR/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in patients with a primary HIV-1 infection | |||||||||||||
| Medical condition: Treatment of HIV infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2023-000044-34 | Sponsor Protocol Number: BT200-VWD2B | Start Date*: 2024-08-14 | |||||||||||
| Sponsor Name:Medical University of Vienna, Department of Clinical Pharmacology | |||||||||||||
| Full Title: Efficacy and Safety of BT200 (rondoraptivon pegol) in Patients with Type 2B von Willebrand disease | |||||||||||||
| Medical condition: patients with type 2B Von Willebrand Disease with thrombocytopenia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-005686-20 | Sponsor Protocol Number: 004 | Start Date*: 2012-08-20 | |||||||||||
| Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
| Full Title: A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients ... | |||||||||||||
| Medical condition: Patients with Complicated Intra-Abdominal Infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) ES (Prematurely Ended) PT (Completed) GR (Completed) LT (Completed) LV (Completed) EE (Completed) BG (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-001900-36 | Sponsor Protocol Number: FFA115285 | Start Date*: 2011-09-26 | |||||||||||
| Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
| Full Title: FFA115285: A randomised, double-blind, double-dummy, placebo controlled multi-centre study to evaluate the efficacy and safety of fluticasone furoate inhalation powder and fluticasone propionate in... | |||||||||||||
| Medical condition: Asthma | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-019844-38 | Sponsor Protocol Number: A6141116 | Start Date*: 2010-08-12 | |||||||||||
| Sponsor Name:Pfizer, S.A | |||||||||||||
| Full Title: A double-blind, randomized, placebo-controlled trial evaluating the safety and efficacy of early the treatment with Eplerenone in patients with acute myocardial infarction. Estudio doble ciego, al... | |||||||||||||
| Medical condition: Infarto agudo de miocardio | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) SK (Completed) CZ (Completed) HU (Completed) GB (Completed) DE (Completed) NL (Completed) GR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-004167-22 | Sponsor Protocol Number: PGT307 | Start Date*: 2008-01-23 | |||||||||||||||||||||
| Sponsor Name:Cell Therapeutics, Inc. | |||||||||||||||||||||||
| Full Title: Paclitaxel poliglumex (CT-2103)/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer (NSCLC) in Women with Estradiol > 30 pg/ml | |||||||||||||||||||||||
| Medical condition: Advanced Non-small Cell Lung Cancer (NSCLC) in women. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
| Trial protocol: HU (Completed) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2011-005707-32 | Sponsor Protocol Number: MK-7655-003 | Start Date*: 2012-07-13 | ||||||||||||||||
| Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | ||||||||||||||||||
| Full Title: A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients wit... | ||||||||||||||||||
| Medical condition: Patients with Complicated Urinary Tract Infection at least 18 years of age, with a diagnosis of either complicated cUTI or acute pyelonephritis | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: ES (Prematurely Ended) GR (Completed) LV (Completed) BG (Completed) PL (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.